Outcomes of surgery for hepatocellular carcinoma with tumor thrombus in the inferior vena cava or right atrium

被引:37
作者
Sakamoto, Kazuhiko [1 ]
Nagano, Hiroaki [1 ]
机构
[1] Yamaguchi Univ, Grad Sch Med, Dept Gastroenterol Breast & Endocrine Surg, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan
关键词
Hepatocellular carcinoma; Surgery; Tumor thrombus; Inferior vena cava; Right atrium; HEPATIC VASCULAR EXCLUSION; SURGICAL-TREATMENT; RESECTION; VEIN; THROMBECTOMY; CHEMOEMBOLIZATION; CHEMOTHERAPY; MANAGEMENT; EXTENSION; SURVIVAL;
D O I
10.1007/s00595-017-1619-2
中图分类号
R61 [外科手术学];
学科分类号
摘要
The prognosis of hepatocellular carcinoma (HCC) patients with tumor thrombus (TT) in the inferior vena cava (IVC) or right atrium (RA) is extremely poor. We reviewed the recent surgical treatments and outcomes of this form of advanced HCC. TT is classified into three types according to its anatomic location relative to the heart: the inferior hepatic type (type I), where the TT is in the IVC below the diaphragm; the superior hepatic type (type II), where the TT is in the IVC above the diaphragm, but still outside the RA; and the intracardiac type (type III), where the TT is above the diaphragm and has entered the RA. Type I can be treated relatively easily by standard radical hepatectomy. For type II, the intrathoracic IVC is approached via the abdominal cavity and an incision in the diaphragm with total hepatic vascular exclusion (THVE). For type III, hepatectomy plus thrombectomy is generally performed under cardiopulmonary bypass. If the TT is only just inside the RA, THVE can be performed by mobilizing the liver caudally. The median overall survival of HCC patients with TT in the IVC or RA, who undergo curative resection, is 19.0-30.8 months. As postoperative recurrence is likely to develop, even after curative surgery, effective postoperative adjuvant chemotherapy is required.
引用
收藏
页码:819 / 824
页数:6
相关论文
共 45 条
[1]  
Asahara T, 1999, HEPATO-GASTROENTEROL, V46, P1862
[2]  
Ayoola E A, 1994, Afr J Med Med Sci, V23, P61
[3]   MAJOR HEPATIC RESECTION UNDER TOTAL VASCULAR EXCLUSION [J].
BISMUTH, H ;
CASTAING, D ;
GARDEN, OJ .
ANNALS OF SURGERY, 1989, 210 (01) :13-19
[4]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[5]   Hepatocellular carcinoma with intra-atrial tumor thrombi - A report of three cases responsive to thalidomide treatment and literature review [J].
Chang, JY ;
Ka, WS ;
Chao, TY ;
Liu, TW ;
Chuang, TR ;
Chen, LT .
ONCOLOGY, 2004, 67 (3-4) :320-326
[6]   Intrapericardial isolation of the inferior vena cava through a transdiaphragmatic pericardial window for tumor resection without sternotomy or thoracotomy [J].
Chen, T. W. ;
Tsai, C. H. ;
Chou, S. J. ;
Yu, C. Y. ;
Shih, M. L. ;
Yu, J. C. ;
Hsieh, C. B. .
EJSO, 2007, 33 (02) :239-242
[7]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[8]  
Chun YH, 2011, ANTICANCER RES, V31, P4641
[9]  
European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.ejca.2011.12.021, 10.1016/j.jhep.2011.12.001]
[10]  
Florman S, 2009, AM SURGEON, V75, P1104